(NASDAQ: ATYR) Atyr Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.82%.
Atyr Pharma's earnings in 2026 is -$75,122,000.On average, 12 Wall Street analysts forecast ATYR's earnings for 2026 to be -$62,819,231, with the lowest ATYR earnings forecast at -$78,742,059, and the highest ATYR earnings forecast at -$36,010,088. On average, 11 Wall Street analysts forecast ATYR's earnings for 2027 to be -$52,540,433, with the lowest ATYR earnings forecast at -$80,662,597, and the highest ATYR earnings forecast at -$25,721,491.
In 2028, ATYR is forecast to generate -$13,825,914 in earnings, with the lowest earnings forecast at -$71,059,907 and the highest earnings forecast at $81,279,913.